Skip to main content
Evidence Snapshot

MDA-MB-435

CHEMBL614697 CELL-LINE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:49Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614697
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats MDA-MB-435 as ChEMBL target CHEMBL614697. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
MDA-MB-435
CELL-LINE · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL614697
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why MDA-MB-435 matters

As of 2026-09-14

MDA-MB-435 is reviewed as MDA-MB-435; the current evidence base includes 30 approved drugs, 34101 compounds, and 1731 assays, with lead potency reaching pChEMBL 9.8.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 30 approved drugs, 34101 compounds, and 1731 assays for this target. The dominant activity type is IC50. CHEMBL56157 is the current potency anchor at pChEMBL 9.8.

Use CHEMBL56157 as the tractability anchor when discussing potency (pChEMBL 9.8).

Activity source · ChEMBL 36 via Core Engine
30 approved pChEMBL 9.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why MDA-MB-435 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

34101
Total Compounds
1731
Total Assays
30
Approved Drugs
IC50: 2670.0, KI: 28.0, EC50: 30.0, KD: 1.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL56157
 9.8 IC50 —
No preferred name
CHEMBL3633920
 9.7 IC50 —
No preferred name
CHEMBL428647
 9.7 IC50 Approved
No preferred name
CHEMBL5435771
 9.7 IC50 —
No preferred name
CHEMBL6966
 9.6 IC50 Approved

Approved Drugs

Structure Compound First Approval
PALBOCICLIB
CHEMBL189963
 2015
LAPATINIB
CHEMBL554
 2007
SUNITINIB
CHEMBL535
 2006
ERLOTINIB
CHEMBL553
 2004
EPIRUBICIN
CHEMBL417
 1999
TOPOTECAN
CHEMBL84
 1996
DOCETAXEL
CHEMBL3545252
 1995
PACLITAXEL
CHEMBL428647
 1992
MITOXANTRONE
CHEMBL58
 1987
DIGITOXIN
CHEMBL254219
 1982
VERAPAMIL
CHEMBL6966
 1981
DAUNORUBICIN
CHEMBL178
 1979
TAMOXIFEN
CHEMBL83
 1977
DIGOXIN
CHEMBL1751
 1975
DOXORUBICIN
CHEMBL53463
 1974
VINBLASTINE
CHEMBL159
 1965
VINCRISTINE
CHEMBL90555
 1963
FLUOROURACIL
CHEMBL185
 1962
COLCHICINE
CHEMBL107
 1961
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:49Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614697